Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Diabetes

Ready-to-Use Glucagon Pen Now Available for Severe Hypoglycemia

Brian Park, PharmD

July 7, 2020

Xeris Pharmaceuticals announced the launch of Gvoke HypoPen™ (glucagon) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.

General Endocrinology

First Oral Somatostatin Analog Approved for Acromegaly Treatment

Brian Park, PharmD

July 6, 2020

The FDA has approved Mycapssa® (octreotide; Chiasma) capsules for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Androgen and Reproductive Disorders

Clinically Meaningful Pain Reduction Observed With Relugolix in Endometriosis Trial

Brian Park, PharmD

July 1, 2020

Positive topline results were announced from the phase 3 SPIRIT 1 study investigating relugolix (Myovant Sciences), in combination with estradiol and norethindrone acetate, in women with pain associated with endometriosis.

Diabetes

FDA Approves Metoclopramide Nasal Spray for Diabetic Gastroparesis

Brian Park, PharmD

June 29, 2020

The FDA has approved Gimoti™ (metoclopramide; Evoke Pharma) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

General Endocrinology

Oral Contraceptive With Novel Estrogen Under FDA Review

Brian Park, PharmD

June 29, 2020

The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).

Bone Metabolism

Burosumab Approved for Treatment of Tumor-Induced Osteomalacia

Brian Park, PharmD

June 26, 2020

The FDA as approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.

Diabetes

New Rapid-Acting Insulin Lispro Approved by FDA

Brian Park, PharmD

June 19, 2020

The FDA has approved Lyumjev™ (insulin lispro-aabc injection; Lilly) to improve glycemic control in adults with type 1 and type 2 diabetes.

Diabetes

FDA Approves Long-Acting Insulin Glargine Injection for T1D, T2D

Brian Park, PharmD

June 19, 2020

The FDA has approved Semglee™ (insulin glargine injection; Mylan and Biocon) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.